Who: Sanofi/Atomwise
What: Sanofi is partnering with Atomwise in a five-target discovery alliance using the AI-focused company’s AtomNet computational discovery and research...
Sanofi Looks To Atomwise For More AI Help
Deal Snapshot: Following its January AI discovery alliance with Exscientia, Sanofi will employ Atomwise’s platform technology against five undisclosed drug targets.
More from Deals
• By
Arvinas and Pfizer have just filed the potential first-in-class protein degrader vepdegestrant, but its diminished commercial prospects after mixed Phase III data mean Pfizer could exit.
• By
As the patent protection clock ticks down on Merck’s flagship blockbuster Keytruda, the company is reported to be pursuing the inflammation and immunology biotech. Such a move would bulk up its sparse I&I pipeline.
• By
Plus deals involving Roche/Vividion, Alto/Chase, Biogen/City Therapeutics, Sanofi/Nurix and Naya/Invo.
• By
Pursuing first-in-class molecular glue degraders using undruggable targets could eventually help Degron Therapeutics land sizable asset-based deals, CEO Lily Zou tells Scrip.
More from Business
• By
As the patent protection clock ticks down on Merck’s flagship blockbuster Keytruda, the company is reported to be pursuing the inflammation and immunology biotech. Such a move would bulk up its sparse I&I pipeline.
• By
EFPIA says reforms make the continent less attractive for innovative firms.
• By
Plus deals involving Roche/Vividion, Alto/Chase, Biogen/City Therapeutics, Sanofi/Nurix and Naya/Invo.